10.12.2015

Prostate cancer test kit instructions

Prostate test kit Home for testing PSA levels of the blood and determine if there are any problems. Our home prostate test kit is an easy and dependable way to measure the PSA (Prostate Specific Antigen) level in your blood - which is useful to help in diagnosing problems with the prostate. The prostate test should be stored at room temperate away from direct sunlight, moisture and heat. Prostate disease may exist without any symptoms, however, one of the first signs of prostate disease is normally having difficulty with urination. To access our page dealing extensively with the prostate gland, diseases of the prostate, treatment of prostate disease and cancer, as well as possible ways to help prevent prostate problems, please click here. The prostate gland is part of the male reproductive system and its function is to add some secretions that make up semen. This refers to the uncontrolled malignant growth of cells in the prostate gland and the risk of prostate cancer increases with age and tends to occur in men over 50. Prostate cancer can range from being a very slow growing tumor which causes very little trouble, to a fast growing, aggressive, life threatening tumor. EARLY DIAGNOSIS OF PROSTATE CANCER IS VERY IMPORTANT AS MOST MEN CAN BE TREATED SUCCESSFULLY WITHOUT HARMING SEXUAL FUNCTIONING. The first step toward diagnosing prostate disease include a digital examination by your medical practitioner and a blood PSA test. Hold the Medlance in your one hand and twist off the protective sealing cap with your other hand and pull it off. Firmly press the Medlance against the selected fingertip, which has been sterilized, with an alcohol swab (included in our test) and press the button to release the needle. The needle will automatically eject itself from the sheath of the Medlance and penetrate the skin. Gently massage the finger towards the puncture site to obtain the volume of blood required.
Apply the end of the blood collection pipette to the blood flow to draw blood into the pipette without depressing the bulb of the pipette. Ensure that the pipette is filled to the line on the stem, and avoid drawing up air bubbles. Apply the blood from the pipette into the round sample well of the cassette by pressing the bulb. Cut the end of the sealed pipette containing the diluent and add 3 (three) drops of the reagent to the sample well.
ANY POSITIVE RESULT must immediately be brought to the attention of your medical practitioner. PSA Tests are one of your first line of defenses in the early detection of prostate cancer.
Certain conditions of the prostate may raise the level of a substance produced by the prostate gland called prostate specific antigen - or PSA. A PSA blood test is a laboratory procedure that measures the amount of prostate specific antigen in your blood. The PSA Screening Test combines the convenience of a home sample collection with the accuracy of a certified clinical laboratory determination. The home PSA Screening Test provides you with an accurate, convenient, and cost-effective way to measure your PSA blood level. Since the risk for prostate cancer increases with age, it is recommended that PSA testing be performed annually for all men once they reach 50 years of age. Men in high-risk groups, such as African Americans and those with blood relatives who have had prostate cancer, should begin testing at age 40 and consult with their health care professional for advice on more frequent testing.
The Home PSA Test provides the same clinical results that can be obtained from a local laboratory, but without the inconvenience of keeping an appointment and the need to draw blood from the arm. Q: Can I have my results sent to my doctor's or business' address instead of my home address?
A: Yes, results can be sent to your doctor's office, or to your business, or to your wellness clinic. A new genetic test to gauge the aggressiveness of prostate cancer may help tens of thousands of men each year decide whether they need to treat their cancer right away or can safely monitor it. The new test, which goes on sale Wednesday, joins another one that recently came on the market.
Doctors say tests like these have the potential to curb a major problem in cancer care—overtreatment.
A study he led of the newest test—the Oncotype DX Genomic Prostate Score—is set for discussion Wednesday at an American Urological Association meeting in San Diego. The results suggest the test could triple the number of men thought to be at such low risk for aggressive disease that monitoring is a clearly safe option. This undated photo provided by Genomic Health shows Andy Dang, a lab assistant at the company, labeling cancer tissue sample transfer tubes for an RNA extraction process.
Independent experts say such a test is desperately needed but that it's unclear how much information this one adds or whether it will be enough to persuade men with low-risk tumors to forgo treatment, and treat it only if it gets worse. One man may view a 15 percent chance that his tumor is aggressive as low risk "but someone else might say, 'Oh my God, let's set the surgery up tomorrow,'" he said.
Also unknown: Will insurers pay for the expensive test without evidence it leads to better care or saves lives? The newest test was developed by Genomic Health Inc., which has sold a similar one for breast cancer since 2004. The company will charge $3,820 for the prostate test and says it can save money by avoiding costlier, unnecessary treatment. Both companies can sell the tests without Food and Drug Administration approval under separate rules that govern lab diagnostics.
This 2012 image provided by Myriad Genetics shows packaging for their PROLARIS sample kits for assessing prostate cancer risk. A third study used single needle-biopsy samples from 395 UCSF patients scheduled to have their prostates removed.


Using one current method, 37 of the 395 men would have been called very low risk and good candidates for monitoring. UCSF just got a federal grant to see how men choose treatments and whether this test might sway them.
Dean Smith, 60, a retired marketing executive from Mill Valley, California, is following his doctor's advice to monitor the cancer he was diagnosed with in March. At least six of his friends suffered side effects ranging from urinary leakage to inability to have sex after having their prostates removed. A genetic pattern could predict how aggressive prostate cancer is before treatment, and whether the disease will come back in men who have already been treated, according to research published in the Lancet Oncology. A new urine test can help aid early detection of and treatment decisions about prostate cancer, a study from the University of Michigan Comprehensive Cancer Center and the Michigan Center for Translational Pathology finds.
The prostate-specific antigen test, commonly known as the PSA test, is valuable in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer, a Mayo Clinic study has found. Researchers in Japan have created a genetic test that will help doctors diagnose prostate cancer. Alcohol-craving rats have provided researchers with a detailed look into the complicated genetic underpinnings of alcoholism.
New research has identified how cells protect themselves against 'protein clumps' known to be the cause of neurodegenerative diseases including Alzheimer's, Parkinson's and Huntington's disease.
In one of the largest international genetic studies of congenital heart disease (CHD), researchers have discovered gene mutations linked to three new rare congenital heart disorders.
Scientists have discovered 15 genome sites - the first ever - linked to depression in people of European ancestry.
Researchers are closer to finding a better way to treat children with a rare metabolic disorder called MPS I. A new test may help prostate cancer victims determine how aggressive to get with their treatment.
The test gauges the aggressiveness of prostate cancer and may help tens of thousands of men each year decide whether they need to treat their cancer right away or can safely monitor it.
Doctors say tests like these have the potential to curb a major problem in cancer care a€” over treatment. A study he led of the newest test a€” the Oncotype DX Genomic Prostate Score a€” is set for discussion Wednesday at an American Urological Association meeting in San Diego. The company will charge $3,820 for the prostate test and says it can save money by avoiding costlier, unnecessary treatment. Dean Smith, 60, a retired marketing executive from Mill Valley, Calif., is following his doctor's advice to monitor the cancer he was diagnosed with in March. The website has been optimised for modern web browsers; for the best experience, please update your browser now. A testing kit used to detect prostate cancer at Connolly Hospital in Blanchardstown has been withdrawn after it was found to be faulty.
Mayo General Hospital is reviewing the results of almost 13,000 tests for prostate cancer after it emerged the model of kits used on patients was faulty and resulting in artificially high readings. News that such a high number of tests are being reviewed comes after Connolly Hospital in Blanchardstown, Dublin, said it had withdrawn the kits after they were found to be faulty. The kits, manufactured by Siemens, are used to measure PSA, a protein made by the prostate gland and which, when raised, may indicate the presence of prostate cancer. They were used at Blanchardstown hospital between February 2013 and June 2013 and in Mayo General between July 2012 and June 2013. A total of 12,866 tests were carried out in Mayo General in the period and in a statement the hospital said its review would determine how many results were elevated as a result of the faulty equipment.
In Blanchardstown, some 2,186 patients were tested during the period and of these, 162 received a result which may have indicated a need for further investigation. In a statement, the HSE said it was reviewing the results of these 162 patients in Blanchardstown to determine if further actions were necessary. PSA tests at Connolly Hospital are currently being sent to Beaumont Hospital for analysis where the Siemens kits are not in use. Mayo General Hospital said an alternative method of testing had been in place since July when the issue with the Siemens kit emerged. A statement from the hospital added that since late June, a notice for doctors had been attached to all PSA test results from the new method, informing them a new test was being used and alerting them to the elevated levels in the now discontinued Siemens testing kit.
ProGRP prostate tumor marker lung cancer elisa test kit, View tumor, KEWEI Product Details from Beijing Kewei Clinical Diagnostic Reagent Inc.
Double antibody sandwich EIA for quantitative detection of ProGRP-a new tumor marker of small cell lung cancer (SCLC). The test should be used as a screening test and as an aid to diagnosing elevated levels of PSA.
Symptoms include a weak stream of urine, passing water for a long time, straining to urinate, unable to urinate or having to pass water at night. It is a small chestnut-shaped organ that is located just below the bladder in front of the rectum and surrounds the urethra like a doughnut. Prostate cancer is the second most lethal cancer in men and accounts for one of one in ten of all cancer deaths in men in developing countries. BEFORE CONTINUING - carefully read the instructions on how to use the Medlance finger pricker. It does not cause pain, and the finger prick that is formed is just large enough to squeeze out the required amount of drops of blood. Wait up to 15 minutes for weaker positives and to make sure that a negative test result is confirmed. You can read more on internet shopping security, delivery times and our terms or go to the fax order page. Small amounts of this substance get into the bloodstream and can be measured by a PSA blood test. While elevated levels of PSA are not harmful, they are an important signal of possible prostate disease.


With it, four drops of blood are taken from a micro-nick of the finger, placed on a special collection card to dry, inserted into the special mailer provided, and then sent (postage paid) to the CLIA certified laboratory for analysis. If you are unable to retrieve your test results, you must call the lab directly at 847-537-9600 between 9am-4pm CST. Peter Carroll, right, at the UCSF Medical Center in San Francisco on Thursday, May 2, 2013. Both analyze multiple genes in a biopsy sample and give a score for aggressiveness, similar to tests used now for certain breast and colon cancers. Prostate tumors usually grow so slowly they will never threaten a man's life, but some prove fatal and there is no reliable way now to tell which ones will.
Conversely, the test also suggested some tumors were more aggressive than doctors had believed. The company's new genetic test to gauge the aggressiveness of prostate cancer may help tens of thousands of men each year decide whether they need to treat their cancer right away or can safely monitor it. Doctors at first were leery of it until studies in more groups of women proved its value, and the same may happen with the prostate test, said Dr. 24, 2010 image provided by Genomic Health shows the packaging for their Oncotype DX kit for assessing prostate cancer risk.
Another test for assessing prostate cancer risk that came out last summer—Prolaris by Myriad Genetics Inc.—sells for $3,400. This kit made available in 2012 will be joined by another genetic test to gauge the aggressiveness of prostate cancer may help tens of thousands of men each year decide whether they need to treat their cancer right away or can safely monitor it. Eric Klein, chief of urology at the Cleveland Clinic, who led early development of the Oncotype prostate cancer test. They measured the activity of hundreds of genes thought to be involved in whether the cancer spread beyond the prostate or proved fatal. The gene test accurately predicted the aggressiveness of their cancer once doctors were able to see the whole prostate after surgery. Kevin McVary, chairman of urology at Southern Illinois University School of Medicine and a spokesman for the Urological Association, said the test must be validated in more men before it can be widely used. It is caused by a deficiency of the key enzyme IDUA needed to break down complex sugars in cells. 24, 2010 photo provided by Genomic Health shows the packaging for their Oncotype DX kit for assessing prostate cancer risk. Doctors at first were leery of it until studies in more groups of women proved its value, and the same may happen with the prostate test, said Dr. Another test for assessing prostate cancer risk that came out last summer a€” Prolaris by Myriad Genetics Inc.
The gene test accurately predicted the aggressiveness of their cancer once doctors were able to see the whole prostate after surgery.
Similar steps were being taken in Mayo with a view to offering doctors re-tests for any patients. A spokesman for the HSE was unable to say when analysis of PSA tests would resume at Connolly Hospital. If you require further details regarding the transaction data, please contact the supplier directly.
Any positive results should be followed up by a visit to your doctor who may request further tests. Studies have suggested that an elevated level of PSA is the most useful tumor marker in the diagnosis of prostate cancer.
Carroll, chairman of urology at the University of California, San Francisco says a study he led on a new prostate cancer test - the Oncotype DX Genomic Prostate Score - suggested it could triple the number of men known to be at such low risk for aggressive disease that monitoring is a clearly safe option. Treatment with surgery, radiation or hormone blockers isn't needed in most cases and can cause impotence or incontinence, yet most men are afraid to skip it. The test is planed to be discussed Wednesday, May 8, 2013 at an American Urological Association conference. This kit and another made available in 2012 are intended to gauge the aggressiveness of prostate cancer may help tens of thousands of men each year decide whether they need to treat their cancer right away or can safely monitor it.
Genomic Health has not published any results on the prostate test, another thing that makes doctors wary. Doctors now base risk estimates on factors such as a man's age and how aggressive cells look from biopsies that give 12 to 14 tissue samples. The new test is planed to be discussed Wednesday, May 8, 2013 at an American Urological Association conference. A second study of biopsies from 167 patients narrowed it down to 81 genes, and researchers picked 17 that seemed to predict aggressiveness no matter the location in the tumor. Smith, 60, said a gene test may have made him more comfortable about his doctor's advice to monitor the cancer he was diagnosed with in March 2013.
Genomic Health has not published any results on the prostate test, another thing that makes doctors wary.
There are however other factors that can cause elevated PSA levels and for more information please click here. Prostate cancer is more common in older men and is the second leading cause of cancer death in American men. Conversely, the test also suggested that some tumors were more aggressive than doctors had believed. The Oncotype test is planed to be discussed Wednesday, May 8, 2013 at an American Urological Association conference. The gene test shifted about half of the men into either a lower or a higher risk category.



Alternative treatment for adrenal cancer metastasis
Alternative treatment for early stage breast cancer walk


Comments to «Prostate cancer test kit instructions»

  1. OCEAN writes:
    Realized the immense primary time in 2015, breast cancer incidence charges.
  2. RICKY writes:
    Weight, but am nonetheless a few kilos off my excellent goal that spiritual meditation lowered.
  3. L_500 writes:
    Deep leisure and relieving necessary time of life massage Cupping bodywork feels simply incredible. And.
  4. Sevimli_oglan writes:
    Solely beneath medical the view that hyperglycemia medicine (TCM) is an ancient set of practices from China.